Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Altimmune, Inc. (ALT)

Altimmune draws $10.0 million third tranche under $125.0 million Hercules loan

Neutral Impact 3 of 5 financing Written later

Altimmune drew $10.0 million as Tranche Three of its $125.0 million Loan and Security Agreement with Hercules Capital after meeting certain clinical and financial milestones. The draw extends the amortization date and interest-only period to June 1, 2028, and adds a minimum cash requirement tied to the loan balance, which shareholders may want to weigh against the company's cash position.

Key points

  • Tranche Three draw of $10.0 million made October 27, 2026, under the loan agreement dated May 13, 2025, as amended November 5, 2025
  • Amortization date and interest-only period extended to June 1, 2028
  • Company must keep Qualified Cash at or above 60% of outstanding Term Loan Advances principal
  • A 1.0% Tranche Facility Charge was netted from funding; end-of-term charge is 6.25% of amounts funded

The filing

CompanyAltimmune, Inc. (ALT)
Form8-K, current report
Filed with the SECOct 29, 2026, 7:03 AM ET
Accession number0001326190-26-000060

Items reported: 2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.